Jiyoon et al. developed a novel capture platform utilizing four antibodies against renal cell carcinoma (RCC) CTCs, including EpCAM, carbonic anhydrase IX (CA9), epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met). Here, MET is linked to hereditary clear cell renal cell carcinoma.